Literature DB >> 6774663

Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa.

A R White, K R Comber, R Sutherland.   

Abstract

Azlocillin was relatively ineffective against actively growing cultures of Pseudomonas aeruginosa in tests of bacteriolytic and bactericidal activity in which ticarcillin demonstrated pronounced bactericidal effects over a wide range of concentrations. Microscopic observation showed that azlocillin generally induced the formation of filamentous cells of P. aeruginosa which lysed only slowly, but ticarcillin caused the production of spheroplasts and subsequent rapid lysis. During the course of the bactericidal tests, azlocillin was inactivated, presumably by the beta-lactamase produced by P. aeruginosa, and the filamentous cells resumed normal cell division and growth. In contrast, there was no loss of ticarcillin activity, and there was no evidence of resumption of growth of P. aeruginosa in the presence of ticarcillin. These results suggest that the different bactericidal effects demonstrated by azlocillin and ticarcillin against P. aeruginosa are related primarily to dose-related differences in inhibition of cell wall synthesis and secondarily to the instability of azlocillin to pseudomonal beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6774663      PMCID: PMC283961          DOI: 10.1128/AAC.18.1.182

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates.

Authors:  H Noguchi; M Kubo; S Kurashige; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

2.  [Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria].

Authors:  H B König; K G Metzger; R P Mürmann; H A Offe; P Schacht; W Schröck
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

5.  Azlocillin: in vitro studies of a new semisynthetic penicillin.

Authors:  D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

6.  Comparative antibacterial activity of azlocillin, mezlocillin, carbenicillin and ticarcillin and relative stability to beta-lactamases of pseudomonas aeruginosa and klebsiella aerogenes.

Authors:  M J Basker; R A Edmondson; R Sutherland
Journal:  Infection       Date:  1979       Impact factor: 3.553

7.  In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae.

Authors:  P P Shah; D J Briedis; H G Robson; J P Conterato
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

8.  PC-904, a new semisynthetic penicillin.

Authors:  G P Bodey; S Weaver; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

9.  Azlocillin and mezlocillin: new ureido penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

10.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

View more
  7 in total

Review 1.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

2.  Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa.

Authors:  M M McFarland; E M Scott; A Li Wan Po
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

3.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients.

Authors:  L Jadeja; R Bolivar; V Fainstein; M Keating; K McCredie; M Hay; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

5.  Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa.

Authors:  S B Calderwood; A Gardella; A M Philippon; G A Jacoby; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

6.  Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; M A Shaffer
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

7.  Repurposing celecoxib as a topical antimicrobial agent.

Authors:  Shankar Thangamani; Waleed Younis; Mohamed N Seleem
Journal:  Front Microbiol       Date:  2015-07-28       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.